Cytolytic peptide nanoparticles ('NanoBees') for cancer therapy

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 3, 2011, Pages 318-327

  Pan, Hua ^a   Soman, Neelesh R ^a   Schlesinger, Paul H ^a   Lanza, Gregory M ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER THERAPEUTICS; CANCER THERAPY; COATED NANOPARTICLES; DELIVERY VEHICLE; NANOCARRIERS; NEW APPLICATIONS; NON-SPECIFICITY; PERFLUOROCARBONS; THERAPEUTIC APPLICATION; THERAPEUTIC POTENTIALS;

LIPOSOMES; PEPTIDES; PHOSPHOLIPIDS; SURFACE ACTIVE AGENTS;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROCARBON; LIPOSOME; MELITTIN; NANOBEES; NANOCARRIER; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER THERAPY; CYTOLYSIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SAFETY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DEATH; DRUG DELIVERY SYSTEMS; HUMANS; MELITTEN; NANOPARTICLES; NEOPLASMS; PEPTIDES;

EID: 79953270044     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.126     Document Type: Article

References (47)

1. Giuliani A, Pirri G, Nicoletto S. Antimicrobial peptides: an overview of a promising class of herapeutics. Cent Eur J Biol 2007, 2:1-33.
2. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006, 24: 1551-1557.
3. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 2008, 1778:357-375.
4. Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005, 62: 784-790.
5. Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 2006, 7: 653-663.
6. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Teran LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 2010, 135:1-11.
7. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 2006, 15:933-946.
8. Leuschner C, Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 2004, 10:2299-2310.
9. Hansel W, Enright F, Leuschner C. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol Cell Endocrinol 2007, 183-189.
10. Hansel W, Leuschner C, Enright F. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol Cell Endocrinol 2007, 269:26-33.
11. Kumar CS, Leuschner C, Doomes EE, Henry L, Juban M, Hormes J. Efficacy of lytic peptide-bound magnetite nanoparticles in destroying breast cancer cells. J Nanosci Nanotechnol 2004, 4:245-249.
12. Bechinger B. Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. J Membr Biol 1997, 156:197-211.
13. Tosteson MT, Tosteson DC. The sting. Melittin forms channels in lipid bilayers. Biophys J 1981, 36: 109-116.
14. DeGrado WF, Musso GF, Lieber M, Kaiser ET, Kezdy FJ. Kinetics and mechanism of hemolysis induced by melittin and by a synthetic melittin analogue. Biophys J 1982, 37:329-38.
15. Lee MT, Chen FY, Huang HW. Energetics of pore formation induced by membrane active peptides. Biochemistry 2004, 43:3590-3599.
16. Yang L, Harroun TA, Weiss TM, Ding L, Huang HW. Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J 2001, 81:1475-1485.
17. Lee MT, Hung WC, Chen FY, Huang HW. Mechanism and kinetics of pore formation in membranes by water-soluble amphipathic peptides. Proc Natl Acad Sci U S A 2008, 105:5087-5092.
18. Hui L, Leung K, Chen HM. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res 2002, 22: 2811-2816.
19. Papo N, Seger D, Makovitzki A, Kalchenko V, Eshhar Z, Degani H, Shai Y. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res 2006, 66: 5371-5378.
20. Hoskin DW. Studied on anticancer activities of antimicrobial peptides. Studied on Anticancer activities of antimicrobial peptides. BBA-Biomembranes 2008, 1778:357-375.
21. Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts T, Smit JJ, Borst P. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res 1990, 50: 1779-1785.
22. Ohsaki Y, Gazdar AF, Chen HC, Johnson BE. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res 1992, 52:3534-3538.
23. Soman NR, Lanza GM, Heuser JM, Schlesinger PH, Wickline SA. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. Nano Lett 2008, 8: 1131-1136.
24. Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, Arbeit JM, Wickline SA, Schlesinger PH. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 2009, 119: 2830-2842.
25. Blondelle SE, Houghten RA. Probing the relationships between the structure and hemolytic activity of melittin with a complete set of leucine substitution analogs. Pept Res 1991, 4:12-18.
26. Habermann E, Zeuner G. Comparative studies of native and synthetic melittins. Naunyn Schmiedebergs Arch Pharmakol 1971, 270:1-9.
27. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005, 23:983-987.
28. Partlow KC, Chen J, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, Nolta JA, Caruthers SD, Lanza GM, Wickline SA. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007, 21: 1647-1654.
29. Pan D, Lanza GM, Wickline SA, Caruthers SD. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol 2009, 70: 274-285.
30. Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng 2009, 37:1922-1933.
31. Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, Edwards S, Onthank D, Silva P, Yalamanchili P, et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003, 18:627-641.
32. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005, 53:621-627.
33. Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, Lanza GM. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J 2008, 22: 2758-2767.
34. Falck E, Rog T, Karttunen M, Vattulainen I. Lateral diffusion in lipid membranes through collective flows. J Am Chem Soc 2008, 130:44-45.
35. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005, 57:559-577.
36. Kaneda MM, Sasaki Y, Lanza GM, Milbrandt J, Wickline SA. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 31:3079-3086.
37. Partlow KC, Lanza GM, Wickline SA. Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials 2008, 29:3367-3375.
38. Culp WD, Neal R, Massey R, Egevad L, Pisa P, Garland D. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res 2006, 5:1332-1343.
39. Arbeit JM, Munger K, Howley PM, Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 1994, 68:4358-4368.
40. Pan H, Myerson JW, Ivashyna O, Soman NR, Marsh JN, Hood JL, Lanza GM, Schlesinger PH, Wickline SA. Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J 2010, 24: 2928-2937.
41. Flaim SF. Artif Cells Blood Substit Immobil Biotechnol 1994, 22:1043-1054.
42. Kaufman R. Emulsions and emulsion stability. In: Sjoblom J, ed. From Clinical Development of Perfluorocarbon-based Emulsions as Red Cell Substitutes. New York: Marcel Dekker; 1996, 343-367.
43. Riess JG. Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artif Organs 1984, 8:44-56.
44. Riess JG, Le Blanc M. Perfluoro compounds as blood substitutes. Angew Chem Int Ed Engl 1978, 17: 621-634.
45. Kemeny DM, Harries MG, Youlten LJ, Mackenzie-Mills M, Lessof MH. Antibodies to purified bee venom proteins and peptides. I. Development of a highly specific RAST for bee venom antigens and its application to bee sting allergy. J Allergy Clin Immunol 1983, 71: 505-514.
46. Kemeny DM, MacKenzie-Mills M, Harries MG, Youlten LJ, Lessof MH. Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens. J Allergy Clin Immunol 1983, 72:376-385.
47. Nordvall SL, Uhlin T, Einarsson R, Johansson SG, Ohman S. Bee keepers' IgG and IgE antibody responses to bee venom studied by means of crossed radioimmunoelectrophoresis. Clin Allergy 1984, 14:341-350.